For the analysis of dose-response relationship under the assumption of ordered alternatives several global trend tests are available. Furthermore. there are multiple test procedures which can identify doses as effective or even as minimally effective. In this paper it is shown that the principles of multiple comparisons and interim analyses can be combined inflexible and adaptive strategies for dose-response analyses; these procedures control the experimentwise error rate.
INTRODUCTION
THE FIRST QUESTION in dose-response analysis is whether a monotone trend across dose groups exists. This leads to global trend tests, where the global level (familywise error rate in a weak sense) is controlled. In clinical research, one is additionally interested in which doses are effective, which minimal dose is effective, or which dose steps are effective, in order to substantiate the choice of a dose. Dose differences are considered effective if they are clinically relevant and statistically significant. Therefore, multiple comparisons which control the experimentwise level (familywise type-I error Reprint address: Prof. Dr. Walter Lehmacher, lnstitut fur Medizinische Statistik, Informatik und Epidemiologie der UniversiM zu Koln, Joseph-Stelzmann-Str. 9, D-50931, Koln. Germany. E-mail: Walter.Lehmacher@ medizin.uni-koeln.de. rate in a strong sense) are necessary. The global and multiplicity aspects are also reflected by the actual International Conference for Harmonization Guidelines (1) for dose-response analysis. Appropriate order restricted tests can be confirmatory for demonstrating a global trend and suitable multiple procedures can identify a recommended dose.
For the global hypothesis, there are several suitable trend tests. For multiple comparisons, there are several approaches for multiple test procedures, some of which are described in the following. It is easy to perform global tests in group sequential or adaptive interim versions, but it seems that there are only a few methods which combine multiple test procedures with interim analyses. In this paper, some new approaches are proposed for the combination of these multiple and sequential dose-response analyses, which can link proof of global trend with proof of efficacy of a chosen dose. Sequential procedures can be especially useful in this area because the multiplicity of this problem makes a reasonable sample size calculation difficult.
TESTS OF TREND
K groups with increasing dose levels are considered, where the smallest dose is often the null-dose (placebo) as a control. A one-way layout with nk experimental units tested at the k-th dose level, k = 1, . . . , K, is considered. All xlli observations are assumed to be mutually independent with xb -N(Pk, o'), lowing, a monotone dose-response relationship is assumed: pl I . . . I p K . The global hypothesis is Ho: pI = . . . = pK, and the trend alternative is I H I : pI I . . . I pK with at least pI c pK. Related trend tests are reviewed in Tamhamet al. (2) . Most are based on special contrasts (eg, Helmert contrasts or simple pairwise contrasts between the maximal and minimal dose). Phillips (3) described methods for sample size estimation in the randomized k-sample design including single-step dose-response studies. Recently, a review of the performance of several tests of trend for dose-response studies was given by Phillips (4). Here a detailed discussion of the performance of these trend tests is not repeated, because in the framework of this paper all such test statistics can be used providing one considers their well-known pros and cons. k = l , . . ., K , and i = 1 , . . . , &. h the fol-
MULTIPLE TEST PROCEDURES
Three multiple test procedures which can be extended to designs with interim analyses are mentioned here.
A-priori Ordered Hypotheses
The family of the K -1 elementary hypotheses which contain the smallest dose group is considered, that is, H l k : pI = . . . = pry k = 2, . . . , K. Then for K = 3, 4, 5 one obtains the following families of hypotheses:
As usual, the definition H I . ,
. t : PI = p2 = . . . = pk is used; the monotonicity implies H I , .
= Hlk. For each K , these families of K -I hypotheses are closed under intersection. Under the assumption of a monotone dose-response relationship all relevant hypotheses which are necessary to identify an (minimally) effective dose are included. In practical applications, the recommended dose will be chosen among the effective doses by carefully considering the magnitude of the observed benefits and side effects.
For this family of hypotheses the closed test procedure is identical to the method of a-priori ordered hypotheses, where the hypotheses are tested step by step, beginning with the global hypothesis Ho = HIK, followed by HI.K-1, HI.K-2, . . . , H I 3 and ending with the "smallest" hypothesis H I 2 . All tests are performed at local level a, and all hypotheses are rejected as long as significance at level a is reached; if a test for a hypothesis H I k is not significant at level a, H I , is not rejected, and no further test (for Hlh-l, HIm-2, etc.) is necessary because no further rejection is possible. For a more detailed description of this a-priori method see Hothorn and Lehmacher (5), Kieser and Lehmacher (6) . or Maurer et al. (7) . For local tests of these elementary hypotheses, all (local) trend tests can be chosen (eg, linear contrasts or comparisons of highest vs. lowest doses), as mentioned earlier. In view of the monitonicity, these tests should be 1-sided. The assumption of monotonicity can be omitted, because the a-priori method works generally with each predefined order of hypotheses. In this case, however, pairwise t-tests should be preferred as local test statistics to trend tests. Some other multiple testing methods fail to control the experimentwise error rate if monotonicity is not given; see Bauer (8) .
The Closed Test Procedure
The K -1 elementary hypotheses &+I stating the identity of two neighboured dose groups are considered, that is, H I 2 : pI = p 2 , H?3 : p2 = p3, . . . , HK-1.K : pK-I = pK. The family of hypotheses is chosen, which is generated by all intersections of these elementary hypotheses. As usual, the abbreviation HklkZ , , , I : pA, = . . . pk, is used. For example, for K = 3, 4, 5 the closed systems of hypotheses are given by the families:
For each K , these families of hypotheses are closed under intersection by definition. They consist not only of simple pairwise comparisons such as HI23 = Hl3, but where the partition hypotheses are tested with a test for the "smallest" partial hypothesis, for example, HI?/, is tested by a level-a-test for H l z , which is evidently a level-a-test for HlyW as well. As a consequence, HM can be tested only after the rejection of H12, and according to the general closed test principle after the rejection of all other inducing hypotheses Ho, H2M, and so forth. As tests for the simple pairwise comparison hypotheses all (local) trend tests (see above) can be chosen. The above mentioned Rom procedure is "uniformly better" than the a-priori method, because after the rejection of a simple pairwise comparison hypothesis H I k of the family described in the above a-priori ordered hypotheses section, only additional partial hypotheses induced by H I k can be tested without loss of power concerning these K -1 tests.
The Bonferroni-Holm Procedure
Here the K -1 elementary hypotheses of neighboured comparisons Hkk+l : pk = pk+I are tested according to the Bonferroni-Holm method; see Budde and Bauer (1 1). This procedure has the primary goal of indentifying effective dose steps. This method, however, has bad power characteristics if the investigated doses are too close together.
SEQUENTIAL TEST PROCEDURES

Group Sequential Procedures
For many of the global trend tests the classical group sequential test procedures can be directly performed with 1-sided tests; see De-Mets and Ware (12) . Bauer and Budde (13) applied these 1-sided group sequential tests to multiple comparisons concerning neighboured dose groups in combination with the Bonferroni-Holm and the a-priori ordered methods.
Adaptive Interim Analyses
Bauer and Kohne (14) proposed procedures with one (or two) adaptive interim analyses, which, in contrast to group sequential designs, allow for a new estimation of the final sample size using the results of the interim analysis. The approach is based on the combination of the independent 1 -sided p-values of the sequences of the study by Fisher's combination test. For a=O.O5, and one interim analysis and one null hypothesis to be tested in confirmatory analysis, this procedure works as follows: Let pI denote the 1sided p-value of the first sequence of the study. Ifpl 2 a,,, the trial stops without rejection of the null hypothesis. If p , I a,, the null hypothesis can be rejected and the trial can stop. If pI E (aI; a,,) , no final decision can be made, and the second sequence has to be planned. For example, al = 0.023 for a,, = 0.5.
Let p z denote the 1-sided p-value of the test statistic generated by the data of the second sequence. If p lp z I 0.0087 (ie, Fisher's product criterion) then the null hypothesis can be rejected.
The procedure allows a free, that is, adaptive choice of sample sizes after an interim analysis. A similar adaptive approach was proposed by Proschan and Hunsberger (15) . Recently, a modification of the classical group sequential procedures was proposed (Lehmacher, Wassmer [ 16] ), which allows for data-driven sample size reestimation after each of the interim analyses; this approach is essentially based on the combination of the @-'-transformation of the independent pvalues. Such adaptive interim analyses are of great importance especially in dose-response analyses, because here in most cases no valid sample size estimation is possible, and therefore the idea of an internal pilot study looks attractive. Because the adaptive methods of Bauer-Kohne and Lehmacher-Wassmer are based only on the combination of independent p-values, they have the additional advantage that a change of the test statistic is possible, too. Even a change of the hypotheses to be tested is possible, say, H I in the first sequence and Hz in the second sequence. In this case, however, a significant result in general enables only the rejection of the global intersection hypothesis Ho = H, fl Hz. Bauer and Rohmel (17) applied the Bauer-Kohne procedure to dose-response analyses, where a change of dose groups (ie, a change of hypotheses) is admitted. This approach has the primary goal of demonstrating a global dose-response relationship, and in their paper it is only mentioned that after the rejection of the global hypothesis Ho, a closed test procedure can follow.
For many trials which aim to demonstrate only a global trend, a fixed sample size design may be sufficient. But even in these simple cases, group sequential trials can reduce the average sample number (ASN). The multiplicity of the additional proof of effective doses makes a sample size calculation essentially more complicated, and sequential approaches are especially useful. Therefore, multiple comparisons within group sequential approaches are particularly proposed in the following section.
COMBINATION OF MULTIPLE AND SEQUENTIAL PROCEDURES
All types of interim analyses (group sequential or adaptive) can be combined with multiple test procedures (a-priori ordered, closed test, or Bonferroni-Holm) described above.
The general construction rule is: "Each hypothesis Hi of the family of hypotheses is tested with a sequential analysis at local level a, or the related p-value is calculated. It is locally rejected, if it is rejected in one of the interim or final analyses of the respective sequential test, taking into account the aadjustments induced by the performance of interim analyses." An hypothesis Hi is rejected if the multiple test procedure allows for the rejection of H, (possibly in dependence from other rejections).
In the a-priori and closed test procedures,
each hypothesis H, is tested at local level a;
in the Bonferroni-Holm method the p-values are compared with the K -1 adjusted levels a / ( Kl), a / ( K -2), . . . , a/2, a.
Evidently, these procedures control the experimentwise error rate a. Flow charts of the a-priori method with K = 3 and of the closed test procedure with K = 2 are given for designs with one interim analysis in Figures 1  and 2 . For a detailed description of the decision rules see Kieser, Bauer, and Lehmacher (1 8).
In practical applications, relevant shortcuts in dependence of early rejections are possible: If an hypothesis is rejected at an interim analysis, certain dose groups can be eliminated in the following sequences. In adaptive interim analyses, the sample sizes can be recalculated for the second (or third) Sequence 1 sequence; even unbalanced sample sizes can be considered.
The adaptive interim approaches enable further flexibilities of the study conduct: If after an interim analysis a certain dose group gives no hope of a relevant contribution, in the second sequence this dose group can be cancelled, even without acceptance or rejection of related hypotheses. For testing a local (intersection) hypothesis in these adaptive approaches, only independent p-values have to be combined: In the closed test procedure, in the second sequence the needed p-value of an intersection hypothesis can be "substituted" by a p-value of one of its inducing hypotheses (by an a-priori definition). This is again possible because a level-a-test for an inducing hypothesis Hi is also a level-atest for an intersection hypothesis Hi f l Hi.
For example: If with K = 3 after the interim analysis the largest dose group has to be dropped (eg, for safety reasons), in the closed test procedure (see Figure 2) for the test of the global hypothesis Ho, the p-value for Ho = HIz3 from the first sequence has to be combined with the p-value of H I 2 from the second sequence. The same strategy can be used if the method of a-prion ordered hypotheses is chosen. Additionally in the adaptive interim approaches, the test statistic can be changed, depending upon the type of contrasts which seem most appropriate. leading to the rejection of Ho and thus demonstrating the efficacy of the extract with the higher content of hyperforin. The U-test for H 1 2 showed a 1-sided p-value of plz = 0.19 > a,. Therefore, the null hypothesis concerning the comparison between placebo and the Hy-pericum extract with a content of only 0.5 % hyperforin could not be rejected in the interim analysis. Due to the small difference in HAM-D between placebo and the extract with the lower hyperforin content the study was stopped with this result. In principle, a second sequence could have been planned for testing HI2, where the 1-sided p-value must fall short of 0.0087/0.19 = 0.0458.
DISCUSSION
In principle, all of the sequential and multiple procedures mentioned can be combined. Due to the complexity of the problem, however, an optimal procedure cannot be derived in general. The choice of the test statistic, and the multiple and sequential procedures must be determined by the well-known pros and cons of these procedures. Because valid sample size estimations are rarely available, the combinations of the procedures described in this paper are suitable to join pilot and confirmative studies. For identifying primarily minimally effective doses, a simple but rather effective combination is the a-priori method (or the slightly more complicated but generally "better" Rom method) with the adaptive interim analyses based on simple pairwise contrasts. Further, the assumptions of variance homogeneity are not necessary, if only pairwise contrasts with the Welch modification as local test statistics are used. Related nonpara-metric versions or trend tests for binary data are available; therefore, all the procedures proposed can be applied essentially for the nonnormal situation, too.
